FR3190M - New drug, in particular for the treatment of uric acid elimination disorders. - Google Patents

New drug, in particular for the treatment of uric acid elimination disorders.

Info

Publication number
FR3190M
FR3190M FR951380A FR951380A FR3190M FR 3190 M FR3190 M FR 3190M FR 951380 A FR951380 A FR 951380A FR 951380 A FR951380 A FR 951380A FR 3190 M FR3190 M FR 3190M
Authority
FR
France
Prior art keywords
treatment
uric acid
new drug
acid elimination
elimination disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR951380A
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf SA filed Critical Roussel Uclaf SA
Priority to FR951380A priority Critical patent/FR3190M/en
Application granted granted Critical
Publication of FR3190M publication Critical patent/FR3190M/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/44—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3
    • C07D311/46—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3 unsubstituted in the carbocyclic ring
    • C07D311/48—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 with one hydrogen atom in position 3 unsubstituted in the carbocyclic ring with two such benzopyran radicals linked together by a carbon chain

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
FR951380A 1963-10-22 1963-10-22 New drug, in particular for the treatment of uric acid elimination disorders. Expired FR3190M (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR951380A FR3190M (en) 1963-10-22 1963-10-22 New drug, in particular for the treatment of uric acid elimination disorders.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR951380A FR3190M (en) 1963-10-22 1963-10-22 New drug, in particular for the treatment of uric acid elimination disorders.

Publications (1)

Publication Number Publication Date
FR3190M true FR3190M (en) 1965-03-15

Family

ID=8814901

Family Applications (1)

Application Number Title Priority Date Filing Date
FR951380A Expired FR3190M (en) 1963-10-22 1963-10-22 New drug, in particular for the treatment of uric acid elimination disorders.

Country Status (1)

Country Link
FR (1) FR3190M (en)

Similar Documents

Publication Publication Date Title
FR3069M (en) New drug, in particular for the treatment of protein anabolic disorders.
FR1215M (en) New drug, in particular for the treatment of disorders due to hyperestrogenia or hypoandrogenia.
FR2963M (en) New drug, in particular for the treatment of protein anabolic disorders.
FR3851M (en) New drug in particular for the treatment of hypercholesterolemia and the resulting disorders.
FR3845M (en) New drug in particular for the treatment of hypercholesterolemia and the resulting disorders.
FR3672M (en) Medicinal product based on nicotinic acid derivatives for the treatment of circulatory disorders.
FR2739M (en) New drug, in particular for the treatment of blood coagulability disorders.
FR3190M (en) New drug, in particular for the treatment of uric acid elimination disorders.
FR2746M (en) New drug for the treatment of uric acid elimination disorders.
FR2576M (en) New drug, in particular for the treatment of blood coagulability disorders.
FR3066M (en) New drug, in particular for the treatment of postprandial or chronic hyperlipemia.
FR3532M (en) New drug, in particular for the treatment of hypercholesterolemia and the resulting disorders.
FR3395M (en) New drug, in particular for the treatment of neurodepressive states and anxiety psychoses.
FR2683M (en) New drug, in particular for the treatment of blood coagulability disorders.
FR2913M (en) New drug, in particular for the treatment of protein anabolic disorders.
FR3269M (en) New drug, in particular for the treatment of protein anabolic disorders.
FR3096M (en) New drug in particular for the treatment of states of adynamia.
FR3031M (en) New drug in particular for the treatment of hypercholesterolemia and the resulting disorders.
FR3392M (en) Dermatological medicinal product, in particular for the treatment of oozing eczema.
FR1780M (en) New drug in particular for the treatment of disorders of protein anabolism.
FR1203M (en) New drug, in particular for the treatment of disorders due to hyperestrogenia or hypoandrogenism.
FR2478M (en) New drug, in particular for the treatment of blood circulation disorders due to hypotension.
FR1829M (en) New drug, in particular for the treatment of blood coagulability disorders.
FR1830M (en) New drug in particular for the treatment of follicle-stimulating hyperactivity.
FR3641M (en) New drug in particular for the treatment of states of adynamia.